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Abstract Children with steroid-resistant nephrotic syn-
drome (SRNS) are at risk of developing renal failure. We
report here the results of a single-center retrospective
observational study of the remission rate in pediatric
patients with SNRS receiving tacrolimus. Serial renal
biopsies from children on tacrolimus therapy were evalu-
ated for tubulointerstitial fibrosis and transforming growth
factor-β immunostaining. Of the 16 children with SRNS,
15 went into complete remission after a median of 120 days
of therapy. Nine children were able to stop steroids, while
the others were on tapering doses. Forty-seven percent had
relapses, most of which were steroid-responsive. Serial
renal biopsies were obtained from seven children after a
median treatment duration of 24 months; two of these
children had increased tubulointerstitial fibrosis and four
showed increased transforming growth factor-β tissue
staining. Children with worsening histological findings
were younger. There was no significant association between
tacrolimus exposure and biopsy changes, although the
average trough level was higher in those children with
worsening histological findings. In conclusion, tacrolimus
may be a safe and effective alternative agent for inducing
remission in children with SRNS. However, caution needs
to be taken when prescribing this agent due to its narrow
therapeutic index. Serial renal biopsies are necessary to
check for subclinical nephrotoxicity, especially in younger
children and those with higher trough levels.
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Introduction
Although steroid resistant nephrotic syndrome (SRNS)
represents a small fraction of all pediatric nephrotic
syndrome (NS) cases, it contributes disproportionately to
end stage renal disease (ESRD) [1]. Renal survival rates
vary somewhat based on the underlying histology but
average 50–60% for children with idiopathic focal segmen-
tal glomerulosclerosis (FSGS), the most common histology
in pediatric SRNS [2]. Notwithstanding the risk of
progressive renal impairment in children with SRNS, the
successful induction of remission, even partial, is associated
with the preservation of renal function and excellent long-
term outcome [2, 3]. Several different therapies have been
attempted, all with variable degrees of success. Some of the
more commonly used ones include cyclophosphamide
(CPM) [4, 5], cyclosporine (CyA) [6, 7] and various
combinations of these. All of these approaches have
problems. Some entail the need for repeated peripheral
intravenous (IV) access (or a more permanent central
venous access) [8]; others have been associated with
serious infections [9]. Therapy with CyA has its own
unique problems, including relapses after withdrawal [10,
11], the development of secondary CyA resistance [11, 12]
and CyA toxicity [11].
The data currently available on the use of tacrolimus
(Tac), a calcineurin inhibitor (CNI), in children with SRNS
are very limited. Theoretically, Tac has many properties that
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transplant population where Tac has been shown to be more
potent [13], with more reliable monitoring of its exposure
using trough determinations [14, 15] and lower cosmetic
side-effects [13]. Whether these benefits of Tac are also
applicable in the setting of NS, where the kinetics are likely
different, has not been studied. Nevertheless, at our center,
we have been using Tac as the preferred CNI in all settings
since July 1995. The purpose of the study reported here was
to describe both the excellent remission rate achieved in our
subjects using this approach and the factors associated with
subclinical nephrotoxicity as seen on serial renal biopsies in
children treated with prolonged courses of Tac. To the best
of our knowledge, there are no published data on the
histological evolution of SRNS based on follow-up biopsies
obtained from children treated with Tac for SRNS.
Methods
Medical records of children with SRNS evaluated at our
center between July 1995 and January 2008 were abstracted
for data. Proteinuria was quantitated using the urine
protein-to-creatinine ratio (Up/c) (mg/mg), and estimated
glomerular filtration rate (eGFR) was calculated using the
previously validated Schwartz formula [16].
NS The constellation of nephrotic range
proteinuria (Up/c>2.5),
hypoalbuminemia (serum albumin<
2.5 g/dL) and edema
SRNS Lack of resolution of proteinuria (Up/
c>0.2) and/or lack of normalization of
the serum albumin (serum albumin<
3.5 g/dL), after at least 6 weeks of daily
steroid therapy
Complete
remission (CR)
Normalization of the Up/c (< 0.2) and
of the serum albumin (> 3.5 g/dL)
Partial remission
(PR)
At least a 50% reduction in the Up/c but
a lack of normalization, and a serum
albumin of ≥2.5 g/dL
Biopsy data All biopsies were re-evaluated in a blinded
manner. Trichrome- and hematoxylin/eosin-stained sections
were evaluated for the extent of tubular atrophy (TA),
interstitial fibrosis (FIB) and arteriolar hyalinosis. The total
area of the tissue showing TA and FIB, excluding the sub-
capsular region, was used to quantitate the extent of TA and
FIB. Any significant FIB, even if not in the classic ‘striped’
pattern was taken into account. Paraffin-imbedded sections
of tissue were used to cut new blocks for transforming
growth factor (TGF)-β staining. The method is described in
detail in a previous article [17]. Very briefly, tissue samples
were deparaffinized, rehydrated and then allowed to interact
overnight with an anti-TGF-β antibody for isoforms 1, 2
and 3 (Fitzgerald Industries Int, Concord, MA) by an
immunoperoxidase technique. Renal tubular immunoreac-
tivity for TGF-β isoforms was evaluated, blinded, by
assessing the percentage of nuclear staining. Appropriate
positive (placenta and kidney) and negative (kidney)
controls were used.
Statistical analyses The paired Student’s t test was used to
compare initial and follow-up laboratory and biopsy data,
the Spearman correlation test was used to compare changes
in the histology and TGF-β staining and the unpaired t test
was used to analyze the effect of variables on worsening
histology/TGF-β staining. Analyses were performed using
SPSS software ver. 16.0 (SPSS, Chicago, IL). A p value
of<0.05 was considered to be statistically significant.
The study was approved by the University of California
Davis Institutional Review Board.
Results
Demographic data During the study period, 22 children
with SRNS were treated at our center, 16 of whom are
included in this study. Six were excluded since they
presented with NS in the context of other genetic/
metabolic disorders or had infantile NS. Ten subjects
were male. Ethnicity was as follows: six Caucasian, five
Asian, three Hispanic and two African American.
Median (range) age at diagnosis was 5.2 (2–13.3) years.
B a s e do nb i o p s yf i n d i n g s ,e i g h tc h i l d r e nh a dF S G S ,
seven had minimal change disease (MCD) and one had
membranous nephropathy.
Initial clinical course Of the 16 children in the study, 12
had primary steroid resistance, and four developed second-
ary resistance at a median of 7 (range 1–13.5) years after
diagnosis. Of the 12 children with primary SRNS, five were
‘partial responders’ in that they had an improvement, but
not normalization, of their proteinuria (Up/c 0.2–2.5) and a
rise, but lack of normalization, of serum albumin (serum
albumin 2.5–3.4 g/dL). When treatment with Tac was
started, patients had completed a median of 2.6 (range 1.5–
22) months of treatment with oral prednisolone. Four
children were still receiving daily steroids, and 12 were
on alternate day steroids. Prior to the initiation of Tac
therapy, three children had been treated with other
immunosuppressive agents, including a combination of IV
methylprednisolone and oral CPM (n=2), oral CPM alone
(n=1), chlorambucil (n=1) and CyA (n=1). At the start of
Tac therapy, ten of the children were receiving either
1518 Pediatr Nephrol (2009) 24:1517–1523angiotensin receptor blockers (ARB) (n=1), angiotensin
converting enzyme (ACE) inhibitors (n=8) or both (n=1).
The median (range) duration of ACE inhibition/ARB use
prior to the start of Tac therapy was 2.5 (0.5–15) months.
Genetic testing for nephrin and podocin mutations was
performed in 12 of the 16 children (Athena Diagnostics,
Worcester, MA). None of the tested children had mutations
in the podocin gene, and three had DNA sequence
variations in the nephrin gene. One child had a variation
of unknown clinical significance in both gene copies, one
had a single gene variant of unknown significance and one
was heterozygous for the mutation associated with the
Finnish type of congenital NS (with an additional gene
variant of unknown clinical significance). None of the
patients had familial NS.
The initial median (range) Tac dose, chosen empirically,
was 0.1 (0.05–0.2) mg/kg per day. The initial target trough
(determined by high-pressure liquid chromatography) was
set at 5–10 ng/mL. Data on the serum albumin, Up/c and
eGFR at diagnosis, start of Tac therapy and at last follow-
up are presented in Table 1. As seen in Table 1, at the time
of the last follow-up visit (median of 22 months after Tac
start), all laboratory parameters had improved, with no
adverse effect on eGFR.
During follow-up, 15 (94%) of the subjects went into
CR. The one patient with advanced chronic kidney disease
at the start of Tac therapy (FSGS on biopsy) was
unresponsive to treatment and progressed to ESRD. The
median (range) time to PR and CR for the 15 children who
responded was 29 (13–180) days and 120 (16–730) days,
respectively. Three children were outliers and took>
200 days to go into CR; all 3 had rapidly responded to
the initiation of Tac therapy. The time from the start of Tac
therapy to the first sign of response (30% reduction in the
Up/c) in these children was 21 (range 14–129) days. Since
the introduction of Tac was the only intervention performed
in the time period immediately preceding the noted
reduction in proteinuria, these children were assumed to
be Tac responders. The temporal pattern of remission after
the start of Tac therapy is graphically depicted in Fig. 1.
The biopsy revealed that the remission rate was not affected
by any underlying histology or the presence of mesangial
hypercellularity.
Final disposition The Tac doses were increased over time
as necessary to achieve CR if the patients did not show
any acute rise in serum creatinine levels. Dose escalation
was at the discretion of the treating nephrologist. At last
follow-up, the median (range) Tac doses and trough
levels were 0.15 (0.06–0.38) mg/kg per day and 5 (1.8–
12.3) ng/mL, respectively. No significant differences
were seen in Tac dosing/trough among ethnicities. The
mean final Tac trough level in children of Caucasian,
Asian, Hispanic and African-American ethnicities was
5.5, 5.6, 7.3 and 4.3 ng/mL, respectively (p=0.17); the
final Tac dose in these same ethnic groups was 0.12, 0.22,
0.14 and 0.08 mg/kg per day, respectively (p=0.87). Of
the 15 children who responded to Tac, nine were able to
come off steroids; six remained on steroids due to steroid-
responsive relapses (n=3) or as part of their initial steroid-
taper (n=3), only two of whom were receiving daily
prednisolone. The longest steroid-free interval for the nine
children who were taken off steroids was a median (range)
of 28.5 (0.1–54) months. Seven of the 15 children (47%)
had relapses during attempted steroid-taper, of whom six
had steroid-responsive relapses. One child, with FSGS,
did not go into remission despite daily prednisolone
therapy and was taken off Tac. At last follow-up, of the
15 children, 13 were still receiving Tac. The two who were
taken off Tac had frequent relapses and were transitioned
to other regimens. Figure 2 depicts the outcomes in the
children in the form of a flow-diagram.
Table 1 Comparison of laboratory data at various time points in relation to the start of tacrolimus therapy
Laboratory parameter Initial presentation Start of Tac Last follow-up p (Tac vs. last follow-up)
Serum albumin (g/dL) 1.2 (0–2.2) 1.5 (0.8–3.5) 3.8 (1.4–4.7) <0.005
Urine protein/creatinine ratio (mg/mg) 11 (2.8–22) 2.8 (0.7–20) 0.09 (0–11.4) 0.002
eGFR (mL/min per 1.73 m
2) 148 (44–352) 159 (29–295) 145 (21–246) 0.19
eGFR, Estimated glomerular filtration rate; Tac, tacrolimus
All numerical data are presented as the median, with the range in parenthesis
Fig. 1 Temporal pattern of remission after the start of tacrolimus
therapy
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discontinuation of Tac therapy due to an acute rise in serum
creatinine in the setting of dehydration. With hydration, his
renal function improved and Tac was restarted. Two
children developed infectious complications, one with
Salmonella enteritidis gastroenteritis and another with
Streptococcal pneumoniae bacteremia (both were frankly
nephrotic when they developed these). Therapy with Tac
was resumed once the infection resolved. One child was
diagnosed with an Epstein–Barr virus (EBV)-negative
Hodgkin’s lymphoma 6 months after being on Tac. This
child had not been known to have lymphoma at the time of
his presentation with NS, and he had not received any other
immunosuppressive therapy prior to the start of Tac. No
patient developed diabetes.
Serial biopsy data Serial renal biopsies were recommended
for all children receiving Tac for>12 months (n =11); of
these, four children did not undergo a biopsy due to family
refusal (n = 3) or insurance reasons (n = 1). Of the children
who had a repeat renal biopsy, five (71%) had FSGS, one
had MCD and one had membranous nephropathy. The
median (range) duration of Tac therapy before the second
biopsy was 24 (14–56) months. The median (range)
cumulative Tac dose between the two biopsies was 102
(61–256) mg/kg, and the median (range) of the Tac trough
levels between the 2 biopsies was 7.2 (3.4–9.5) ng/ml.
Although there was no significant increase in the median
area with FIB, TA, and tissue staining for any of the
isoforms of TGF-β between the pre- and post-Tac biopsies,
two of the seven children (29%) showed an increase in their
FIB/TA score, four (57%) had increased tissue staining for
TGF-β (only one of whom also had changes visible upon
light microscopy examination), one child each had
increases in TGF-β 2 and TGF-β 3 staining and two
children had increases in both TGF-β 1 and TGF-β 2
staining. There was a strong correlation between changes in
FIB and changes in TA between biopsies (r=0.9, p=0.002).
However, there was no significant correlation between
changes in TGF-β staining (for any isoforms) and changes
in either FIB or TA, or between changes in the three
isoforms of TGF-β (all p>0.05). The biopsies (both initial
and repeat) inallpatientslackedsignificantarteriolarhyalinosis.
We found no significant association between any demographic
parameter/measure of Tac exposure and increased TGF- β
staining (data not shown). Data on factors associated with
increased TA/FIB are depicted in Table 2.
Children with increased TA/FIB were younger. The
duration of Tac exposure, cumulative Tac dose and Tac
trough levels were not significantly associated with changes
in the histological findings. Figure 3 depicts a normal
glomerulus with no TGF- β tissue staining; Figure 4 is a
representative biopsy showing significant and intense
TGF-β tissue staining.
Discussion
Children with SRNS continue to be at high risk of
complications [18]. Moreover, many of the diseases that
present as SRNS in children have a high rate of recurrence
after transplantation [19–21]. Therefore, every possible
attempt needs to be made to induce remission in such
children, while concurrently minimizing the toxicity of the
therapeutic regimens. Cyclosporine A has been used as a
frequent therapeutic agent in patient with SRNS. However,
the long-term use of CyA has been associated with
nephrotoxicity, related to arteriolar vasoconstriction, which
if prolonged could lead to renal ischemia and FIB [22–24].
Fig. 2 Flow-chart depicting
outcomes in study population.
CR Complete remission, SRNS
steroid-resistant nephrotic
syndrome
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course of CyA have shown evidence of FIB and TA in as few as
15–17% of the patients [6, 10]t oa sh i g ha s5 7 %[ 25].
Pediatric experience with Tac in SRNS is limited.
Excluding single case reports, few single-center studies
have been published to date [5, 26–28]. In 2004, Loeffler et
al. described the use of Tac in seven children with SRNS;
six achieved CR and one went into PR after a mean
duration of 2 months of therapy. At last follow-up, five of
the seven were off steroids, although the steroid-free
duration was quite short. Bhimma et al. subsequently
reported a CR rate of 40% and a PR rate of 45% in 20
South African children with SRNS from idiopathic FSGS
who received a 12-month course of Tac. At last follow-up,
only five (25%) remained in CR. Lastly, Gulati et al.
reported a CR rate of 84% in a cohort of North Indian
children treated with Tac and steroids [28]. Our study is the
largest reported study on the use of Tac in North American
children with SRNS, and the only one, to the best of our
knowledge, that has analyzed serial biopsy data. Our
success with the use of Tac in pediatric patients with SRNS
exceeds previously reported data, with all but one child
(94%) achieving CR. The only child who did not respond
had advanced FSGS with an eGFR of 29 mL/min per 1.73
surface area. In our experience, children who respond to
Tac do so shortly after initiation of Tac, with a median time
to laboratory-confirmed improvement of 27 days, although
CR may take longer. Most of our children were able to be
tapered off their steroids (60%). An additional 20% were
still receiving steroids, most of whom were on alternate day
steroids and were being slowly weaned off. During the
steroid-taper, almost half of the children had relapses, of
whom all but one responded to a re-initiation of steroid
treatment. These results support the previous observation
that CNIs work best when used in combination with
steroids. The prolonged use of Tac in these children was
associated with relatively little observed toxicity. While we
cannot discount a contribution of Tac in predisposing one
of our patients to develop lymphoma, the observation that
the tumor was EBV negative makes this less likely.
Moreover, this child’s underlying renal histology showed
MCD, which is known to be associated with Hodgkin’s
lymphoma; the association is even stronger in children with
MCD who are steroid-resistant or -dependant [29, 30].
In order to look more closely for subclinical nephrotox-
icity, we obtained serial renal biopsies from our patients
who went into remission on Tac. Histological examination
of these biopsies revealed that two of seven children had
increased FIB and TA, suggestive of chronic CNI toxicity,
and that four children (57%) had increases in TGF-β tissue
expression, with only one of these four also showing changes on
light microscopy examination. Transforming growth factor-β is
a ubiquitous cytokine with very significant fibrogenic properties;
ithasbeenshowntobeupregulatedinthesettingofCyAtoxicity
in the renal transplant population [31]. Similar effects on TGF-β
expression have been noted with Tac, both in vivo and in vitro
Fig. 4 BiopsywithintenseTGF-βstaining(brown) in renal tubular nuclei Fig. 3 Biopsy with no transforming growth factor (TGF)-β staining
Demographic/Tac exposure variables Worsening histology No histological change p
Age (years) 5.9 12.3 0.03
Duration of Tac duration (months) 27.5 27 0.9
Average inter-biopsy Tac trough (ng/mL) 8.4 5.4 0.16
Inter-biopsy cumulative Tac dose (mg/kg) 72 160 0.16
Table 2 Association between
biopsy changes and demograph-
ic/Tac exposure variables
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of TGF-β upregulation [32, 34] ,w h i c hm a yb er e l a t e dt oa
differential effect of Tac on the expression of TGF-β receptors
[35] and also due to the fact that FKBP12, the carrier protein
for Tac, is a negative regulator of the type I TGF-β receptor
[36]. The clinical significance of the increased TGF-β
expression in the four patients is unclear. Based on the link
between CNI toxicity and TGF-β, our current observation is
cause for concern since it could be a harbinger of future FIB.
Although we attempted to identify predictors of increasing TA/
FIB, the size of our study sample was limited and did not allow
the use of multivariate analyses. We did find that the study
subjects that had a progression of TA/FIB were younger. The
average inter-biopsy Tac trough was also higher in the cohort
that had worsening histology compared to those with no
histological changes, but this difference was not statistically
significant. Our study was also limited by the lack of serial
biopsies in controls with SRNS who were not receiving Tac,
which would have facilitated us in sorting out the differences in
histological findings between the effect of the natural progres-
sion of the underlying renal disease and the effect of Tac. Such
repeat biopsies are not considered a standard of care. Moreover,
Tac is the only therapy we use in children with SRNS and,
consequently, there was no control population that could be
studied. Nevertheless, we feel that this study provides valuable
information to the practicing nephrologist since it demonstrates
the success that can be achieved using Tac in North American
children with SRNS, with a low risk of clinical toxicity. A
longer follow-up is necessary to monitor renal function in
children treated with Tac. Until such data are available, the
lowest possible dose of Tac necessary to maintain remission
should be used, especially in younger children.
In conclusion, Tac may be a safe and effective alternative in
inducing remission in children with SRNS. The risk of
subclinical nephrotoxicity with Tac as well as the risk of
progressive chronic kidney disease in the absence of remission
being achieved need to be discussed with families, and an
informed decision must be made by the clinical team.
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